Mental Health Clinics in Lacassine, LA Accepting Medicare
1 Mental Health Clinics found. Showing 1 - 1
 Sanctuary Of Louisiana Clinic Counselor - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 21089 South Frontage Road, Lacassine, LA 70650 Phone: 337-936-9197 Fax: 337-588-4179 |
News Archive
CNIO researchers identify new strategy to combat cancer
Scientists from the Spanish National Cancer Research Centre have discovered a new strategy to fight cancer, which is very different from those described to date. Their work shows for the first time that telomeres - the structures protecting the ends of the chromosomes - may represent an effective anti-cancer target: by blocking the TRF1 gene, which is essential for the telomeres, they have shown dramatic improvements in mice with lung cancer.
Scientists explore popular pre-heart transplant therapy's impact on kidney function
Scientists, nephrologists and cardiac surgeons from The Feinstein Institute for Medical Research and Northwell Health's Department of Internal Medicine, Cardiology and Cardio-Thoracic Surgery examined the impact of a popular pre-heart transplant therapy on the kidney in a study published today by The Clinical Journal of the American Society of Nephrology.
FDA updates dosing recommendation for Valcyte medication
The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant.
Study aims to elucidate the prevalence and etiology of PoPH in patients with chronic liver disease
Portopulmonary hypertension (PoPH) is a form of pulmonary arterial hypertension (PAH). PoPH occurs in approximately 15% of patients with PAH, and is reportedly found in 2-6% of patients with portal hypertension and 1-2% of patients with liver cirrhosis according to studies from Europe and America.
Phase III clinical trial results of DAR-31 published
Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company's once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.
› Verified 6 days ago